Ben Pascario, MD
Obstetrics & Gynecology · New York, NYNPI 1174629471
Payments from drug & device makers
Across 120 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$514
- Collegium Pharmaceutical, Inc.$351
- Exact Sciences$276
- Lupin Inc.$173
- Biohaven Pharmaceutical Holding Company Ltd.$167
- Scynexis, Inc.$160
- plus $723 from 16 others
What the payments were for
- Food & beverage$2,364100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $514 |
| Collegium Pharmaceutical, Inc. | 18 | $351 |
| Exact Sciences | 13 | $276 |
| Lupin Inc. | 11 | $173 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $167 |
| Scynexis, Inc. | 6 | $160 |
| Exeltis, USA Inc. | 9 | $154 |
| Therapeuticsmd, Inc. | 6 | $128 |
| Mayne Pharma Commercial LLC | 4 | $65 |
| Almatica Pharma LLC | 2 | $49 |
| Evofem Biosciences, Inc. | 2 | $46 |
| Vertex | 2 | $44 |
| Millicent US Inc | 3 | $44 |
| Duchesnay USA Incorporated | 2 | $32 |
| Amgen | 1 | $26 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Celularity Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Myovant Sciences Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
How this compares
$2,364 in reported general payments places this provider in the 80th percentile of 2,673 obstetrics & gynecology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol (Once Weekly)Estradiol | 39 | $3,337 |
| Terconazole | 39 | $1,014 |
| ProgesteroneProgesterone, Micronized | 34 | $1,005 |
| Raloxifene Hcl | 21 | $874 |
| ValacyclovirValacyclovir Hcl | 13 | $617 |
| Halobetasol Propionate | 14 | $566 |
| Fluconazole | 21 | $295 |
| Ciprofloxacin Hcl | 35 | $175 |
| Doxycycline Hyclate | 11 | $80 |
| Azithromycin | 12 | $56 |
| Amoxicillin | 13 | $35 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in New York
- Jin Hee KimNew York$1M
- Carolyn WesthoffNew York$935K
- Mary PolanNew York$862K
- Steven GoldsteinNew York$557K
- Veronica LernerNew York$368K
- Rachana GavaraNew York$290K
- Taraneh ShirazianNew York$287K
- Lisa EngNew York$237K
- Monica DragomanNew York$230K
- Rachel MaschNew York$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.